How does the disease progress when you have hepatitis C? This is the most important question for all people with hepatitis C. To clarify this question, let’s first look at the general pattern after infection with the hepatitis C virus. HCV RNA can be detected in peripheral blood generally 1 to 3 weeks after hepatitis C virus infects the body, but only 50% to 70% of patients with acute hepatitis C infection can detect anti-HCV when clinical symptoms appear, and after 3 months about 90% of patients are anti-HCV positive. After infection with hepatitis C virus, some of the infected patients will clear the virus automatically and be cured. If the virus remains in the bloodstream for 6 months and is not cleared, the infection becomes chronic. Reports of the rate of chronicity of hepatitis C vary widely, but most are 50-60%, with some reports of 85% of infected individuals becoming chronic. The course of chronic hepatitis C is not as severe as when hepatitis C virus was first recognized. 25% of infected patients have normal liver function and mild liver damage; 60% have mildly elevated transaminases, mild-moderate necroinflammation and very mild liver fibrosis, and their subsequent progression is unclear; it is estimated that most of them will not die from liver disease; 20% of patients with chronic hepatitis C may progress to cirrhosis within 10-20 years. ～The annual incidence of primary hepatocellular carcinoma in patients with cirrhosis is 1-4%. Patients who develop cirrhosis and hepatocellular carcinoma have a significantly lower quality of life and are the leading cause of death in patients with chronic hepatitis C. What factors can influence the progression of hepatitis C disease? Many factors are involved in the ultimate “direction” of hepatitis C, and understanding these factors may play an important role in improving prognosis and taking control of the future. Age and gender of infection can affect the prognosis of hepatitis C. People under 40 years of age and women with hepatitis C virus have a higher rate of spontaneous viral clearance, while people over 40 years of age and men with hepatitis C virus are less likely to have the virus eliminated and to develop cirrhosis and liver cancer. Twenty years after infection with the hepatitis C virus, the incidence of cirrhosis is 10% to 15% in the general population, 2% to 9.4% in children and young women; 20% to 30% in middle-aged men. The prognosis for hepatitis C virus varies depending on the mode of infection. Those infected by blood transfusion generally develop more rapidly, and those infected by sexual transmission have a better prognosis. This may be related to the higher amount of hepatitis C virus entering the body at one time after a blood transfusion. Alcohol is strongly associated with the progression of hepatitis C. Alcohol promotes the proliferation of hepatitis C virus in human hepatocytes, significantly aggravates viremia, and also interferes with the antiviral activity of alpha interferon, reducing the efficacy of interferon. As a result, alcohol drinkers in hepatitis C tend to be more likely to develop cirrhosis and liver cancer. Overlapping infections with other hepatitis viruses, AIDS, schistosomiasis, combined fatty liver, use of hepatotoxic drugs or exposure to toxic substances can all add to hepatitis C and accelerate the progression of liver disease. The most important influencing factor is treatment. The incidence of cirrhosis and hepatocellular carcinoma is significantly lower in patients treated with interferon than in those who are not treated, and the earlier the antiviral treatment after infection, the longer the course of treatment and the better the outcome. Although age and gender of infection are not optional among these influencing factors, patients with hepatitis C can slow or stop the progression of hepatitis C or even achieve recovery through proactive measures such as antiviral therapy, avoidance of alcohol, vaccination against hepatitis B, and prevention of overlapping infections with other viruses.